2751-09-9CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=OLQCLVBQBTUVCEQ-GSELTXNRSA-NSafety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
DescriptionTroleandomycin (2751-09-9) is a macrolide antibiotic. Inhibits cytochrome P450 (IC50 = 0-5 μM), thus blocking CYP450-dependent drug oxidation.
UsesTroleandomycin, is a macrolide antibiotic, sold in Italy and Turkey. It is a derivative of Oleandomycin (O517500), and acts as a CYP3A4 inhibitor, which may cause drug interactions .
UsesAntibacterial.
General DescriptionTriacetyloleandomycin was synthesized by Pfizer Research Laboratories in 1958. It shows a higher and longer-lasting serum level than oleandomycin when administered orally. Triacetyloleandomycin behaves as oleandomycin in vivo, following its hydrolysis by intestinal esterase. However, considerable amounts of the intermediates, the monoacetates and diacetates, are detected in the serum and urine. Prolonged use of triacetyloleandomycin causes damage to the liver as does erythromycin estolate.
No reaction records under the current filter.
Loading…
2751-09-9CHEMBL1200719DefinitionChEBI: A semi-synthetic macrolide antibiotic obtained by acetylation of the three free hydroxy groups of oleandomycin. Troleandomycin is only found in individuals that have taken the drug.